Business
Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders
BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) held today on June 3, 2021. Dr. Simon Pimstone, Executive Chair of Xenon’s Board of Directors stated, “We announced plans for a leadership transition earlier in the year, implemented a seamless succession plan, and effected these appointments at our Annual Meeting. Ian Mortimer, who takes on the role of CEO and joins our board of directors, has worked alongside me for the past seven years and is ideally suited to lead Xenon, together with Sherry Aulin, who was appointed Xenon’s Chief Financial Officer. It has been a privilege to head up this talented executive team while serving Xenon’s shareholders and other stakeholders and I look forward to moving into the role of Executive Chair of the Board to continue to support Xenon’s goal to develop innovative therapeutics to improve the lives of patients with neurological disorders.” Dr. Pimstone continued, “We are truly grateful for Michael Tarnow’s 22 years of service on our Board, including his remarkable, committed leadership as Board Chair. In addition, we wish to recognize the important contributions of Frank Holler, who has been a member of our Board similarly for approximately two decades, including serving as the chair of our Audit Committee and previously serving as Xenon’s founding President and CEO. The strategic advice offered by these long-serving directors is immeasurable, and their counsel helped Xenon achieve its strong position today.” Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, said, “The entire Xenon team wishes to extend its deep gratitude to Simon for his vision and dedication to Xenon over the years, which has resulted in a broad pipeline of neurology-focused therapeutic candidates. Simon’s guidance, leadership and mentorship has positively impacted so many of us, not just at Xenon but across the life sciences sector in Canada. I am excited to take on my new role as CEO, building upon the great amount of momentum in both our proprietary and partnered programs.” Mr. Mortimer added, “We are also pleased to announce that Elizabeth Garofalo was elected to our Board of Directors at the Annual Meeting....